119 related articles for article (PubMed ID: 38472738)
1. Understanding Clinician Preferences for Treatment Attributes in Oncology: A Discrete Choice Experiment of Oncologists' and Urologists' Preferences for First-Line Treatment of Locally Advanced/Unresectable Metastatic Urothelial Carcinoma in Five European Countries.
Panattoni L; Kearney M; Land N; Flottemesch T; Sullivan P; Kirker M; Bharmal M; Hauber B
Pharmacoeconomics; 2024 Mar; ():. PubMed ID: 38472738
[TBL] [Abstract][Full Text] [Related]
2. Correction to: Understanding Clinician Preferences for Treatment Attributes in Oncology: A Discrete Choice Experiment of Oncologists' and Urologists' Preferences for First-Line Treatment of Locally Advanced/Unresectable Metastatic Urothelial Carcinoma in Five European Countries.
Panattoni L; Kearney M; Land N; Flottemesch T; Sullivan P; Kirker M; Bharmal M; Hauber B
Pharmacoeconomics; 2024 Jun; ():. PubMed ID: 38874847
[No Abstract] [Full Text] [Related]
3. Treatment preferences of patients with relapsed or refractory multiple myeloma in the United States, United Kingdom, Italy, Germany, France, and Spain: results from a discrete choice experiment.
Thomas C; Ailawadhi S; Popat R; Kleinman D; Ross MM; Gorsh B; Mulnick S; O'Neill A; Paka P; Hanna M; Krucien N; Molinari A; Gelhorn HL; Perera S
Front Med (Lausanne); 2023; 10():1271657. PubMed ID: 38076274
[TBL] [Abstract][Full Text] [Related]
4. Preferences for Renal Cell Carcinoma Pharmacological Treatment: A Discrete Choice Experiment in Patients and Oncologists.
Fernández O; Lázaro-Quintela M; Crespo G; Soto de Prado D; Pinto Á; Basterretxea L; Gómez de Liaño A; Etxaniz O; Blasco S; Gabás-Rivera C; Aceituno S; Palomar V; Polanco-Sánchez C
Front Oncol; 2021; 11():773366. PubMed ID: 35070976
[TBL] [Abstract][Full Text] [Related]
5. Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment.
Liu FX; Witt EA; Ebbinghaus S; DiBonaventura Beyer G; Shinde R; Basurto E; Joseph RW
Patient Prefer Adherence; 2017; 11():1389-1399. PubMed ID: 28860722
[TBL] [Abstract][Full Text] [Related]
6. Comparing Discrete Choice Experiment with Swing Weighting to Estimate Attribute Relative Importance: A Case Study in Lung Cancer Patient Preferences.
Veldwijk J; Smith IP; Oliveri S; Petrocchi S; Smith MY; Lanzoni L; Janssens R; Huys I; de Wit GA; Groothuis-Oudshoorn CGM
Med Decis Making; 2024 Feb; 44(2):203-216. PubMed ID: 38178591
[TBL] [Abstract][Full Text] [Related]
7. Patient Preferences for Metastatic Hormone-Sensitive Prostate Cancer Treatments: A Discrete Choice Experiment Among Men in Three European Countries.
de Freitas HM; Ito T; Hadi M; Al-Jassar G; Henry-Szatkowski M; Nafees B; Lloyd AJ
Adv Ther; 2019 Feb; 36(2):318-332. PubMed ID: 30617763
[TBL] [Abstract][Full Text] [Related]
8. Patient preferences do matter: a discrete choice experiment conducted with breast cancer patients in six European countries, with latent class analysis.
Stamuli E; Corry S; Foss P
Int J Technol Assess Health Care; 2023 Apr; 39(1):e21. PubMed ID: 37074007
[TBL] [Abstract][Full Text] [Related]
9. Public Preferences for Digital Health Data Sharing: Discrete Choice Experiment Study in 12 European Countries.
Biasiotto R; Viberg Johansson J; Alemu MB; Romano V; Bentzen HB; Kaye J; Ancillotti M; Blom JMC; Chassang G; Hallinan D; Jónsdóttir GA; Monasterio Astobiza A; Rial-Sebbag E; Rodríguez-Arias D; Shah N; Skovgaard L; Staunton C; Tschigg K; Veldwijk J; Mascalzoni D
J Med Internet Res; 2023 Nov; 25():e47066. PubMed ID: 37995125
[TBL] [Abstract][Full Text] [Related]
10. Preferences for first-line treatment of advanced urothelial carcinoma among US practicing oncologists and patients.
Grivas P; Veeranki P; Chiu K; Pawar V; Chang J; Bharmal M
Future Oncol; 2023 Feb; 19(5):369-383. PubMed ID: 36876486
[TBL] [Abstract][Full Text] [Related]
11. Patient Preferences for Treatment Attributes in Inflammatory Bowel Disease: Results From a Large Survey Across Seven European Countries Using a Discrete Choice Experiment.
Fiorino G; Bent-Ennakhil N; Varriale P; Braegger F; Hoefkens E
Inflamm Bowel Dis; 2024 Mar; ():. PubMed ID: 38503480
[TBL] [Abstract][Full Text] [Related]
12. Patients' Preferences for Artificial Intelligence Applications Versus Clinicians in Disease Diagnosis During the SARS-CoV-2 Pandemic in China: Discrete Choice Experiment.
Liu T; Tsang W; Huang F; Lau OY; Chen Y; Sheng J; Guo Y; Akinwunmi B; Zhang CJ; Ming WK
J Med Internet Res; 2021 Feb; 23(2):e22841. PubMed ID: 33493130
[TBL] [Abstract][Full Text] [Related]
13. Economic considerations and patients' preferences affect treatment selection for patients with rheumatoid arthritis: a discrete choice experiment among European rheumatologists.
Hifinger M; Hiligsmann M; Ramiro S; Watson V; Severens JL; Fautrel B; Uhlig T; van Vollenhoven R; Jacques P; Detert J; Canas da Silva J; Scirè CA; Berghea F; Carmona L; Péntek M; Keat A; Boonen A
Ann Rheum Dis; 2017 Jan; 76(1):126-132. PubMed ID: 27190098
[TBL] [Abstract][Full Text] [Related]
14. Patient versus physician preferences for lipid-lowering drug therapy: A discrete choice experiment.
Zhang L; Chen J; Cao Z; Zhang M; Ma R; Zhang P; Yao G; Li X
Health Expect; 2024 Apr; 27(2):e14043. PubMed ID: 38590082
[TBL] [Abstract][Full Text] [Related]
15. What matters most to patients with multiple myeloma? A Pan-European patient preference study.
Janssens R; Lang T; Vallejo A; Galinsky J; Morgan K; Plate A; De Ronne C; Verschueren M; Schoefs E; Vanhellemont A; Delforge M; Schjesvold F; Cabezudo E; Vandebroek M; Stevens H; Simoens S; Huys I
Front Oncol; 2022; 12():1027353. PubMed ID: 36523996
[TBL] [Abstract][Full Text] [Related]
16. Clinician Preferences for Oxybate Treatment for Narcolepsy: Survey and Discrete Choice Experiment.
Morse AM; Krahn L; Flygare J; Kushida C; Thorpy MJ; Athavale A; Gudeman J
Adv Ther; 2023 Jul; 40(7):3199-3216. PubMed ID: 37243863
[TBL] [Abstract][Full Text] [Related]
17. Evaluating Patient Preferences of Maintenance Therapy for the Treatment of Chronic Obstructive Pulmonary Disease: A Discrete Choice Experiment in the UK, USA and Germany.
Lewis HB; Schroeder M; Gunsoy NB; Janssen EM; Llewellyn S; Doll HA; Jones PW; Ismaila AS
Int J Chron Obstruct Pulmon Dis; 2020; 15():595-604. PubMed ID: 32256060
[TBL] [Abstract][Full Text] [Related]
18. Patients' and oncologists' preferences for second-line maintenance PARP inhibitor therapy in epithelial ovarian cancer.
Stone RL; Cambron-Mellott MJ; Beusterien K; Maculaitis MC; Ritz S; Mulvihill E; Monberg M; Szamreta EA; Amin S; McLaurin K
Future Oncol; 2022 Feb; 18(4):491-503. PubMed ID: 34875854
[TBL] [Abstract][Full Text] [Related]
19. How Do Treatment Preferences of Patients With Cancer Compare With Those of Oncologists and Family Members? Evidence From a Discrete Choice Experiment in China.
Zhang M; He X; Wu J; Wang X; Jiang Q; Xie F
Value Health; 2022 Oct; 25(10):1768-1777. PubMed ID: 35710892
[TBL] [Abstract][Full Text] [Related]
20. Oncologist and Patient Preferences for Attributes of CDK4/6 Inhibitor Regimens for the Treatment of Advanced/Metastatic HR Positive/HER2 Negative Breast Cancer: Discrete Choice Experiment and Best-Worst Scaling.
Maculaitis MC; Liu X; Will O; Hanson M; McRoy L; Berk A; Crastnopol M
Patient Prefer Adherence; 2020; 14():2201-2214. PubMed ID: 33177814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
